Author Correction: Global burden of amphetamine, cannabis, cocaine and opioid use in 204 …
#47
Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
This correction to Global Burden of Disease data affects how clinicians understand the actual prevalence and health impact of cannabis use across populations, potentially influencing screening practices and resource allocation in clinical settings. Accurate epidemiological data on cannabis use patterns from 1990-2023 helps clinicians contextualize patient risk factors and substance use trends relevant to their specific communities. The corrected estimates directly inform public health policy that shapes clinical guidelines, insurance coverage decisions, and treatment availability for cannabis-related disorders.
This author correction addresses methodological refinements in a major Global Burden of Disease Study quantifying cannabis use prevalence and disease burden across 204 countries from 1990 to 2023. The correction likely involves clarifications to epidemiological estimates, disability-adjusted life years, or demographic stratification that affect how clinicians interpret global cannabis-related morbidity trends. Understanding accurate prevalence data is essential for clinicians to contextualize patient cannabis use within population-level patterns and to appreciate regional variations in cannabis-related harms and sequelae. The corrected estimates help inform evidence-based counseling regarding cannabis risks and establish a foundation for comparing burden of cannabis use against other substance use disorders in clinical and public health decision-making. Clinicians should reference the corrected data when discussing with patients the documented global health impact of cannabis use, particularly concerning mental health outcomes and cannabis use disorder development in vulnerable populations.
💊 This correction to a major Global Burden of Disease analysis underscores the importance of accurate epidemiological data when counseling patients about cannabis use prevalence and population-level harms. While global surveillance estimates are inherently limited by inconsistent reporting, underdiagnosis, and varying definitions of cannabis use disorders across countries, understanding current burden estimates helps clinicians contextualize individual patient risk within broader public health trends. The inclusion of cannabis alongside amphetamines, cocaine, and opioids in burden calculations reflects growing recognition that cannabis is not risk-free, particularly regarding cognitive effects in adolescents, cannabis use disorder development, and potential psychotic symptoms in vulnerable populations. Clinicians should remain cautious about assuming the relative “safety” of cannabis compared to other substances, as epidemiological burden rankings do not necessarily reflect individual clinical outcomes or the intensity of harms experienced by affected patients. When discussing cannabis use with patients, particularly young people and those with
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
